ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Diflucan®, Pulver zur Herstellung einer Suspension zum Einnehmen und Infusionslösung:Pfizer AG
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
J02AC01 - FluconazoleATC-DDD Version 2016. Source: WHO
J - Antiinfectives for Systemic Use

Antiinfectives are also classified in the following groups:
A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R02AB Antibiotics
S01/
S02/
S03 Eye and ear preparations with antiinfectives
Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use.
Inhaled antiinfectives are classified in J.

The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).

J02 - Antimycotics for Systemic Use
 
J02A - Antimycotics for Systemic Use

This group does not include antimycotics specifically for dermatological use even if they are administered systemically (see D01B).
Antimycotics - see also:
A01AB Antiinfectives and antiseptics for local oral treatment
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
G01 Gynecological antiinfectives and antiseptics
Fumagillin used in the treatment of intestinal microsporidiosis is classified in P01AX.

The DDDs are based on the treatment of systemic mycosis.

J02AC - Triazole and Tetrazole Derivatives

All oral and parenteral formulations of fluconazole are classified here. Fosfluconazole (prodrug of fluconazole) is classified at the same 5th level as fluconazole.
Vaginal formulations of triazole derivatives, see G01AG.

The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.

J02AC01 - Fluconazole
DoseRoute of administrationNote
 P 
 O 
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home